Table 2.

Parameter estimations of the model from the registration file and the final model

Parameters	Estimates in the registration file	Estimates of the final POPPK model (RSE%)
CL/F (L/h)	2.23	3.11 (5%)
F1 (/)*	0.675	0.675
Vc/F (L)*	81.5	81.5
Vp/F (L)*	213	213
Q/F (L/h)*	14.2	14.2
Ka1 (/h)*	0.568	0.568
ALAG1 (h)*	0.459	0.459
Ka2 (/h)*	0.102	0.102
ALAG2 (h)*	16.8	16.8
Dose exponent on Ka1*	−0.5	−0.5
Female on CL/F*,#	0.79	0.79
Asian on CL/F*,#	0.73	0.73
Ω2_CL*	0.213	0.213
Ω2_Vc*	1.06	1.06
Ω2_Ka*	0.437	0.437
Ω2_F1*	0.385	0.05
Ω2_CL:Vc*	0.44	0.44
Residual error	0.254	0.335 (10%)

Ω2_CL variance of IIV on CL, Ω2_Vc variance of IIV on Vc, Ω2_Ka variance of IIV on Ka, Ω2_F1 variance of IIV on F1, Ω2_CL:Vc covariance of CL/F and Vc/F, ALAG1 lag time of depot 1, ALAG2 lag time of depot 2, CL clearance, CL/F apparent plasma clearance, Vc central volume of distribution, Vc/F apparent central volume of distribution, F1 fraction in the absorption depot 1, FDA Food and Drug Administration, IIV inter-individual variability, Ka1 absorption rate constant from depot 1, Ka2 absorption rate constant from depot 2, PK pharmacokinetic(s), POPPK population pharmacokinetic, Q/F apparent distribution rate constant between compartments, RSE relative standard error, Vp/F apparent peripheral volume of distribution

*Value fixed to the FDA registration file

^#Transformed estimates correspond to multiplicative change from the typical PK parameter